Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.
Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.
复制标题
经皮治疗周围血管疾病：糖尿病和炎症的作用。
DOI：
10.1016/j.jvs.2007.02.029
复制
发表时间：
2007
影响因子：
4.3
通讯作者：
Nguyen,LouisL
中科院分区：
文献类型：
--
作者：
Nguyen,LouisL
对于许多美国人来说，外周动脉疾病(PAD)是一个日益严重的健康问题，通常与其他心血管危险因素一起发生，包括糖尿病(DM)、低度炎症、高血压和血脂紊乱。间歇性跛行(IC)是PAD的早期表现，通常会导致活动受限的患者的生活质量下降。尽管近年来经皮外周介入(PPI)技术的广泛应用增加了积极治疗IC的患者的数量，但PPI治疗IC的总体效果尚不为人所知，特别是对于存在血流动力学和功能障碍的糖尿病患者。这篇综述旨在说明如何通过不同的方式来衡量IC的治疗结果，以及糖尿病和炎症如何影响这些结果。在人们更加关注卫生保健资源和临床责任的背景下，更好地了解治疗结果和疗效将有助于我们应对这些复杂的挑战。
Peripheral arterial disease (PAD) is a growing health problem for many Americans and often occurs along with other cardiovascular risk factors, including diabetes mellitus (DM), low-grade inflammation, hypertension, and lipid disorders. Intermittent claudication (IC), an early manifestation of PAD, commonly leads to reduced quality of life for patients who are limited in their ambulation. While recent wide adoption of percutaneous peripheral interventional (PPI) techniques has increased the number patients being aggressively treated for IC, the overall effectiveness of PPI for the treatment of IC is not well known, especially for DM patients who have both hemodynamic and functional obstacles to treatment success. This review is designed to illustrate how treatment outcomes for IC can be measured by different modalities and how diabetes and inflammation can influence those outcomes. In the setting of greater concern for health care resources and clinical accountability, better understanding of treatment outcomes and efficacy will help us manage these complex challenges.